NCT07100184View on ClinicalTrials.gov

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2028

Conditions
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Interventions
DRUG

Disitamab Vedotin combined with Radiotherapy

Disitamab Vedotin (RC-48) injection 2mg/kg, Q2w for 4 circles before radiotherapy and 2mg/kg, Q3w for 8 circles after radiotherapy; Radiotherapy (Whole bladder dose: 25 Gy in 5 doses, QD)

All Listed Sponsors
collaborator

RemeGen Co., Ltd.

INDUSTRY

lead

Peking University First Hospital

OTHER